Nitroxyl progenitors in the treatment of heart failure

Details Nitroxyl progenitors in the treatment of heart failure Nitroxyl progenitors in the treatment of heart failure

2011-01-04

2011-01-04

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S149000, C514S611000

Reexamination Certificate

active

07863262

ABSTRACT:
Administration of an HNO/NO−donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO−donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO−donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO−donors, administration of an HNO/NO−donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO−exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

REFERENCES:
patent: 4539321 (1985-09-01), Campbell
patent: 4954526 (1990-09-01), Keefer
patent: 5039705 (1991-08-01), Keefer et al.
patent: 5212204 (1993-05-01), Keefer et al.
patent: 5789447 (1998-08-01), Wink, Jr. et al.
patent: 5814656 (1998-09-01), Saavedra et al.
patent: 6083515 (2000-07-01), Garvey et al.
patent: 6143734 (2000-11-01), Garvey et al.
patent: RE37116 (2001-03-01), Garvey et al.
patent: 6297260 (2001-10-01), Bandarage et al.
patent: 6323234 (2001-11-01), Garvey et al.
patent: 6936639 (2005-08-01), Wink et al.
patent: 2002/0010146 (2002-01-01), Garvey et al.
patent: 2002/0016322 (2002-02-01), Bandarage et al.
patent: 2002/0119977 (2002-08-01), Kanapure et al.
patent: 2004/0038947 (2004-02-01), Wink et al.
patent: WO 96/32946 (1996-04-01), None
patent: WO 98/43621 (1998-03-01), None
patent: WO 99/33823 (1999-07-01), None
patent: WO-00/28988 (2000-05-01), None
patent: WO 00/67754 (2000-11-01), None
patent: WO 01/45703 (2001-06-01), None
patent: WO 02/060378 (2002-08-01), None
patent: WO-2005/074598 (2005-08-01), None
patent: WO-2005/074598 (2005-08-01), None
Maragos et. al. , J. Med. Chem (1991) 34:3242-3247.
Paolocci et. al. (PNAS (2001) 98:10463-10468).
Remme et. al. (European Heart Journal (2001) 22:1527-1560).
Advisory Action mailed May 25, 2007, for U.S. Appl. No. 10/463,084, filed Jun. 16, 2003, 3 pages (3.00).
Amendment in Response to Final Office Action mailed May 8, 2007, for U.S. Appl. No. 10/463,084, filed Jun. 16, 2003, 13 pages.
Final Office Action mailed Mar. 8, 2007, for U.S. Appl. No. 10/463,084, filed Jun. 16, 2003, 7 pages.
Fukuto, J.M. (2005). “Nitroxyl (HNO): Chemistry, Biochemistry, and Pharmacology,”Annu. Rev. Pharmacol Toxicol. 45:335-355.
Fukuto, J.M. et al. (Apr. 2005). “The Chemistry and Biology of Nitroxyl (HNO): A Chemically Unique Species with Novel and Important Biological Activity,”Chembiochem. 6:612-619.
Miranda, K.M. (2005). “Donors of HNO,”Curr. Top. Med. Chem. 5(7):649-664.
Pagliaro, P. (2003). “Differential Biological Effects of Products of Nitric Oxide (NO) Synthase: It is Not Enough to Say NO,”Life Sci. 73:2137-2149.
Pagliaro, P. (2003). “Nitroxyl Affords Thiol-Sensitive Myocardial Protective Effects Akin to Early Preconditioning,”Free Radic. Biol. Med. 34(1):33-43.
Paolocci, N. (Apr. 29, 2003). “Positive Inotropic and Lusitropic Effects of HNO/NO−in Failing Hearts: Independence from β-Adrenergic Signaling,”PNAS100(9):5534-5542.
Paolocci, N. et al. (Feb. 2007; e-pub. Nov. 29, 2006). “The Pharmacology of Nitroxyl (HNO) and its Therapeutic Potential: Not Just the Janus Face of NO,”Pharmacology and Therapeutics113(2): 442-458.
Thomas, D.D. (2002), “Guide for the Use of Nitric Oxide (NO) Donors as Probes of the Chemistry of NO and Related Redox Species in Biological Systems,” Chapter 8,in Nitric Oxide, Part D: Nitric Oxide Detection, Mitochondria and Cell Functions, and Peroxynitrite Reactions, Academic Press: Amsterdam, pp. 84-105.
U.S. Appl. No. 10/587,644, filed Jul. 27, 2006, by Toscano et al.
U.S. Appl. No. 11/922,793, filed Dec. 21, 2007, by Paolocci et al.
Wink, D.A. et al. (Dec. 2003; first published Jul. 10, 2003). “Orthogonal Properties of the Redox Siblings Nitroxyl and Nitric Oxide in the Cardiovascular System: a Novel Redox Paradigm,”Am. J. Physiol. Heart Circ. Physiol. 285:H2264-H2276.
Fitzhugh et al.,Free Radical Biology&Medicine, vol. 28, No. 10, pp. 1463-1469 (2000).
Harrison's Principles of Internal Medicine, Isselbacher et al., eds., 13thed. vol. 1, 1994, pp. 1002-1008.
Hart et al., Abstract,Am J Physiol Heart Circ Physiol, vol. 281, No. 1, pp. H146-H154 (Jul. 2001).
Ma et al.,PNAS, vol. 96, No. 25, pp. 14617-14622 (1999).
Maragos et al.,J. Med. Chem., vol. 34, No. 11, pp. 3242-3247 (1991).
Pagliaro et al., Abstract 1265,Supplement to Circulation, vol. 104, No. 17, pp. 11-263-11-264 (2001).
Pagliaro et al.,J. Physiol., vol. 536, p. 143P (2001).
Paolocci et al., Abstract,Italian Heart Journal, vol. 2, Suppl. 3, p. 62S (Sep. 2001).
Paolocci et al.,PNAS, vol. 98, No. 18, pp. 10463-10468 (Aug. 28, 2001).
De Witt, B.J. et al. (Nov. 2, 2001). “Comparison of Responses to Novel Nitric Oxide Donors in the Feline Pulmonary Vascular Bed,”Eur. J. Phramacol. 430(2-3):311-315.
Fukuto, J.M. et al. (Nov. 1992). “The Pharmacological Activity of Nitroxyl: A Potent Vasodilator with Activity Similar to Nitric Oxide and/or Endothelium-Derived Relaxing Factor,”J. Pharmacol. Exp. Ther. 263(2):546-551.
Gelvan, D. et al. (Jun. 1, 1991). “Cardiac Reperfusion Damage Prevented by a Nitroxide Free Radical,”Proc. Natl. Acad. Sci. USA88(1):4680-4684.
Li, H. et al. (Apr. 15, 2002). “Polynitroxyl-Albumin (PNA) Enhances Myocardial Infarction Therapeutic Effect of Tempol in Rat Hearts Subjected to Regional Ischemia-Reperfusion,”Free Radic. Biol. Med. 32(8):712-719.
Naughton, P. et al. (2001). “Induction of Haem Oxygenase-1 by Nitroxyl Anion (NO−) in Cardiomyocytes,”J. Physiol531:194P.
Pagliaro, P. et al. (2001). “Is Nitroxyl Anion Involved in Myocardial Protection Against Ischaemia/Reperfusion Injury in Isolated Rat Hearts?”J. Physiol. 536:143P.
Pagliaro, P. et al. (2001). “Nitroxyl Anion is a Preconditioning Agent in Isolated Rat Heart,”Circulation104(17 Suppl.):II-263-II-264, Abstract 1265.
Paolocci, N. et al. (Sep. 2001). “Nitroxyl Anion Improves In Vivo Contractile Function and Promotes Active Relaxation in Experimental Heart Failure,”Italian Heart Journal2(Suppl. 3):62S, Abstract No. 38.
Takahira, R. et al. (Sep. 15, 2001). “Dexamethasone Attenuates Neutrophil Infiltration in the Rat Kidney in Ischemia/Reperfusion Injury: The Possible Role of Nitroxyl,”Free Radic. Biol. Med. 31(6):809-815.
Tosaki, A. et al. (Nov.-Dec. 1992). “Does the Antiarrhythmic Effect of DMPO Originate from its Oxygen Radical Trapping Property or the Structure of the Molecule Itself?”Basic Res. Cardiol. 87(6):536-547.
Vanuffelen, B.E. et al. (Mar. 1, 1998). “Intracellular but not Extracellular Conversion of Nitroxyl Anion into Nitric Oxide Leads to Stimulation of Human Neutrophil Migration,”Biochem. J. 330(Pt. 2) :719-722.
Yu, L. et al. (Mar. 1, 1994). “Nitric Oxide: A Mediator in Rat Tubular Hypoxia/Reoxygenation Injury,”Proc. Natl. Acad. Sci. USA91(5):1691-1695.
Bassani, R.A. et al. (Oct. 1994). “Na-Ca Exchange is Required for Rest-decay but not for Rest-potentiation of Twitches in Rabbit and Rat Ventricular Myocytes,”J. Mol. Cell. Cardiol. 26(10):1335-1347.
Bristow, M.R. (2000). “β-Adrenergic Receptor Blockade in Chronic Heart Failure,”Circulation101:558-569.
The Canadian Cardiovascular Society. (2001). “The 2001 Canadian Cardiovascular Society Consensus Guideline Update for the Management and Prevention of Heart Failure,” twenty-eight pages.
Chavey II, W.E. et al. (Sep. 15, 2001). “Guideline for the Management of Heart Failure Caused by Systolic Dysfunction: Part II. Treatment,”American Family Physic

Affiliated with

Also associated with

Rating

Nitroxyl progenitors in the treatment of heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nitroxyl progenitors in the treatment of heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitroxyl progenitors in the treatment of heart failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2694714